A 29-year-old client with recurrent vulvovaginal candidiasis asks about starting oteseconazole and hopes to become pregnant in the future. Which response by the nurse is best?
1Clarify the prescription because future pregnancy potential makes oteseconazole inappropriate.✓ Correct answer
2Start treatment after one week of contraception and repeat testing before the last dose.
3Start treatment and pause breastfeeding only on the days each capsule is taken.
4Begin after a negative pregnancy test and continue routine reproductive counseling.
Explanation
Oteseconazole is indicated only for females who are not of reproductive potential and is contraindicated in females of reproductive potential, pregnancy, and lactation because its prolonged exposure window prevents adequate mitigation of embryo-fetal risk.
Quick answer Clarify oteseconazole for any female of reproductive potential.
Why this is correct This restriction is broader than short-term contraception during dosing. The nurse verifies reproductive-potential status before therapy rather than attempting to create an unlabeled workaround.
Easy analogy or mental picture Build a medication-safety chain: identify the changing cue, connect it to the labeled toxicity or interaction, interrupt preventable exposure, stabilize the client, and verify a measurable response.
NCLEX decision rule Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.
Why the other choices are wrong Options that continue a suspect exposure, normalize a labeled danger cue, or delay escalation leave the client at risk.
References
1DailyMed: VIVJOA (oteseconazole)Restriction to females not of reproductive potential and contraindications in reproductive potential, pregnancy, and lactation
Oncology medication-safety reviewVerify indication, current assessment, laboratory and oxygen trends, interactions, urgent toxicity cues, authorized action, and measurable follow-up.